Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 12

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 12
---
 issuance of our common stock and entered
into an At The Market Offering Agreement (the “ATM Agreement”) with Rodman & Renshaw LLC under which the Company may
offer and sell shares of its Common Stock, with an aggregate offering amount sold of up to $100,000,000. During the three months ended June 30, 2025, the Company
sold a total of 18,300 shares of its common stock, at a weighted average price of $2.67 for a total proceeds of $47,769, net of costs of $1,032.

On May 19, 2025, Telomir Pharmaceuticals, Inc. (the
“Company”) entered into an agreement to raise $3 million in equity financing through a direct investment by The Bayshore Trust,
an entity affiliated with the Company’s largest shareholder. The transaction was structured as a straight restricted common stock
deal with no warrants. The Company issued 333,333 restricted shares of its common stock, no par value (the “Common Stock”)
at a purchase price of $3.00 per share, representing an 18% premium to the closing share price of the Common Stock of $2.54 on the date
of execution (the “Bayshore Financing”). The Company received the initial payment of $1 million for the Bayshore Financing
on May 20, 2025. In July 2025, an additional 666,666 common shares were issued for $2 million received (See Note 8).

Restricted Stock Units

On May 27, 2025, 400,000 fully vested common shares
were granted for services to the Company’s CEO. The restricted shares were valued at $840,000 based on the stock quoted trading
price at the grant date and were expensed immediately as compensation expense.

Warrants

In
connection with various transactions and the IPO summarized below, the Company issued stock warrants. Warrant activity for the three
months ended June 30, 2025 and 2024 is summarized below:

 Schedule
of warrant activity

    Weighted  

    Weighted  
    Average  

    Number of  
    Average Exercise  
    Remaining Contractual  
    Aggregate Intrinsic 

    Warrants  
    Price  
    Term (Years)  
    Value 
  
    Outstanding as December 31, 2023 
     2,774,057  
    $4.85